- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 19,450 | +2,10 % | MPH Health Care mit Halbjahresverlust durch Insolvenz bei CR Energy | Die MPH Health Care AG hat für das erste Halbjahr 2025 einen Rückgang des Eigenkapitals von 277,9 Millionen Euro auf 205,1 Millionen Euro gemeldet. Der Net Asset Value je Aktie der Berliner Beteiligungs-Gesellschaft... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,375 | -0,87 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| AMARIN | 12,500 | -0,79 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,430 | +1,13 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| MADRIGAL PHARMACEUTICALS | 364,60 | +1,36 % | A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts | ||
| CATALYST PHARMACEUTICALS | 16,785 | -0,80 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 84,00 | +1,82 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance | Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc. Subsidiary PrestoDoctor Now Accepts Cryptocurrency Payments, Including Dogecoin | MESQUITE, NV, Sept. 10, 2025 (GLOBE NEWSWIRE) -- September 10, 2025 - Mesquite, NV - Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation,announced that its wholly owned... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. | NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | Blum Holdings Inc. Reports First Quarter 2025 Financial Results | DOWNEY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the "Company," "Blüm," "Blüm Holdings," "we" or "us"), a California-based publicly traded holding company and cannabis... ► Artikel lesen | |
| BMP PHARMA TRADING | 5,000 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr 2024/25 bestätigt | DJ PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,411 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results | - Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 8,010 | +0,25 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| ALLERGY THERAPEUTICS | 0,087 | 0,00 % | Allergy Therapeutics - Grass MATA MPL Publications in Allergy Journal |
MERUS LABS INTERNATIONAL INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.